ENTELLIGENCE™ Young Investigator Program Charter

ENTELLIGENCE Mission
ENTELLIGENCE is a program for basic science, translation, and clinical research in the field of cardiopulmonary medicine. The ENTELLIGENCE Young Investigator Program (ENTELLIGENCE Program) provides opportunities for individual young investigators to promote quality medical care and enhance patients’ lives by supporting research in pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology. With a strong commitment to research, ENTELLIGENCE provides a program for young investigators at institutions in the US and Canada with research programs in cardiovascular medicine, pulmonary medicine, and rheumatology to explore research in PH.

Conflicts of Interest
ENTELLIGENCE members and affiliates scrupulously avoid any conflict between their respective personal, professional, or business interests and the interests of ENTELLIGENCE, in any and all actions taken by them on behalf of ENTELLIGENCE in their respective capacities. If any ENTELLIGENCE member or affiliate has any direct or indirect interest in, or relationship with, any individual or organization that proposes to enter into any transaction with ENTELLIGENCE, including but not limited to: employment, or rendition of services, personal or otherwise; the award of any grant, contract, or subcontract; such person shall give notice of such interest or relationship and shall thereafter refrain from discussing or voting on the particular process in which he/she has an interest, or otherwise attempting to exert any influence on ENTELLIGENCE, its components, or affiliates to affect a decision to participate or not participate in such a relationship/transaction.

In an effort to be more compliant, the following steps will be taken:
- When a Steering Committee (SC) member wants to support a young investigator as a co-investigator or mentor, the SC member would need to take a 1-year leave of absence at the LOI submission phase.
- When the SC is associated with an institution, they may stay on the committee.

Funding and Role of Funder
The ENTELLIGENCE Program is funded by an independent educational grant from Actelion Pharmaceuticals US, Inc (Actelion). Actelion is not involved in the grant awarding process. Actelion assists in organizing materials that promote and communicate the ENTELLIGENCE mission and activities, with approval of the Steering Committee (SC).

Grants Awarded by ENTELLIGENCE
As a general rule, each year, a total of 4 grants up to $100,000 are awarded annually to qualified investigators who show promise in the investigations of the basic mechanisms, vascular biology, and clinical consequences of PH. The number of grants awarded may be less than four if funding by Actelion is reduced or if the quality of proposals reviewed does not merit funding.

SC Composition
The ENTELLIGENCE SC is comprised of nine (8 members and 1 chair) thought leaders. A pre-requisite is expertise in basic science and/or translational research in pulmonary vascular biology, and/or clinical practice in pulmonary arterial hypertension.

SC Functions
The SC serves as the principal advisor for the ENTELLIGENCE Program and its website, entelligencemd.org. SC members play an integral role in the guidance and overall direction for the ENTELLIGENCE Program and act as grant reviewers and researchers for proposals submitted for the ENTELLIGENCE Program.

The SC serves as the evaluator of the research proposals, reviewing initial Letter of Intent (LOI) submissions via the ENTELLIGENCE website and participating in the Young Investigators Selection Meeting to determine the final awardees.

SC members commit to participate in the following meetings:
- LOI Conference Call – Review LOIs and choose which young investigators will be invited to submit a grant
- Selection Meeting: 1-day meeting (typically held at an airport hotel in late February/early March)
- Award Ceremony (typically held in conjunction with the annual ATS Meeting)

**Master Consulting Agreement (MCA) and Statement of Work (SOW)**
Each calendar year, an amendment to the MCA and SOW must be signed by the SC Chairman and the SC members. The MCA and SOW need to be fully executed with Actelion prior to receiving honoraria.

**Honoraria**
Honoraria are provided on an annual basis to the SC members and the SC chair and are reported in accordance with applicable laws governing industry-physician financial relationships. Fees and reimbursements paid to SC members are subject to Actelion standards, including Fair Market Value payments for consulting services, travel arrangements, and the use of Actelion contract templates. All payments made to SC members who are healthcare providers are subject to Federal and State reporting and disclosure laws.

**Term Limits for SC Chairman and SC Members: Replacement Recommendations**
- Appointment: The duration of SC appointments consists of a 3-year term, beginning in 2013-2014 with an option to renew for 2 additional 3-year terms. No more than 2 SC members may rotate off the Committee per year.
- Chairman: The duration of the chair position consists of a 3-year term, beginning in 2013-2014, with an option to renew for 2 additional 3-year terms, decided by a vote of the SC at the expiration of the first term. The Chairman also has the option of an SC membership for an additional 3-year term.

**Nominations/Discussion/Voting for New SC Members**
The SC collectively votes on appropriate replacements for SC members and the SC chair. The process is as follows:
- Announcement of the Position: Approximately 9 months (and no less than 3 months) prior to the beginning of the next funding cycle,* an announcement is made by the SC Chair that a replacement for an SC vacancy will be needed. A call for nominations by the SC will be made.
- Call for Nominations from SC members: Any SC member may nominate one or more candidates. Considerations for the appointment include the following:

- Current makeup of the SC, with consideration of:
• Areas of expertise
  o Balance between senior and less-experienced members
  o Geographic distribution

- Ability of the SC to adequately review ENTELLIGENCE-related applications
- Avoidance of real or perceived close associations between SC members

• Formal discussion of nominees by the SC to occur not less than 21 days before an official vote. All stakeholders† may comment.

• The sponsor, Actelion, may provide direction for the SC in choosing appropriate candidates and endorse the final nominees. Actelion will use the same criteria for considerations for appointment as cited above.

• After the formal discussion, each SC member will submit a confidential vote to Medtelligence (either via email, or in a meeting).
  - If there are more than 3 nominees, there will be a first vote. The top 3 will then be considered and a final vote taken.

Confidentiality, Privacy, and Non-Disclosure of Materials and Procedures
The applications, proposals, and associated materials made available to reviewers, as well as the discussions that take place during review meetings are strictly confidential and must not be disclosed to or discussed with anyone who has not been officially designated to participate in the review process. Information in any applicant's file will not be used for the benefit of SC members or their colleagues.

*Funding cycle starts immediately after the Award Luncheon, typically held at the ATS Congress in May.
†Stakeholders include SC committee members, Medtelligence, and Actelion.

July 2019